Paper40161336
EGCG's anticancer potential unveiled: triggering apoptosis in lung cancer cell lines through in vitro investigation.
Khair AMB and 3 others. PeerJ, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. EGCG's anticancer potential unveiled: triggering apoptosis in lung cancer cell lines through in vitro investigation. Papers, record 40161336. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40161336
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- EGCG's anticancer potential unveiled: triggering apoptosis in lung cancer cell lines through in vitro investigation.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Catechin | Major topic |
| Apoptosis | Major topic |
| Lung Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Proto-Oncogene Proteins c-akt | |
| Cell Proliferation | |
| Signal Transduction | |
| Cell Line, Tumor | |
| Cell Movement | |
| A549 Cells | |
| Phosphatidylinositol 3-Kinases |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37446908 | Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications. | Molecules | 2023 | https://conductscience.org/library/papers/37446908 | PubMed |
| 2 | 31938038 | Current shreds of evidence on the anticancer role of EGCG in triple negative breast cancer: an update of the current state of knowledge. | Infect Agent Cancer | 2020 | https://conductscience.org/library/papers/31938038 | PubMed |
| 3 | 31013611 | Radioprotective Effect of Walnut Oligopeptides Against Gamma Radiation-Induced Splenocyte Apoptosis and Intestinal Injury in Mice. | Molecules | 2019 | https://conductscience.org/library/papers/31013611 | PubMed |
| 4 | 24366444 | Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. | Oncol Rep | 2014 | https://conductscience.org/library/papers/24366444 | PubMed |
| 5 | 33650320 | Perspectives and controversies regarding the use of natural products for the treatment of lung cancer. | Cancer Med | 2021 | https://conductscience.org/library/papers/33650320 | PubMed |
| 6 | 30058690 | Study of EGCG induced apoptosis in lung cancer cells by inhibiting PI3K/Akt signaling pathway. | Eur Rev Med Pharmacol Sci | 2018 | https://conductscience.org/library/papers/30058690 | PubMed |
| 7 | 32020598 | Lung cancer incidence in young women vs. young men: A systematic analysis in 40 countries. | Int J Cancer | 2020 | https://conductscience.org/library/papers/32020598 | PubMed |
| 8 | 34769263 | Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34769263 | PubMed |
| 9 | 32008337 | Epigallocatechin gallate reduces uric acid levels by regulating xanthine oxidase activity and uric acid excretion in vitro and in vivo. | Ann Palliat Med | 2020 | https://conductscience.org/library/papers/32008337 | PubMed |
| 10 | 37762316 | An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37762316 | PubMed |
| 11 | 29989449 | New options on the horizon for nononcogene addicted non-small-cell lung cancer. | Future Oncol | 2018 | https://conductscience.org/library/papers/29989449 | PubMed |
| 12 | 29791813 | Higher Lung Cancer Incidence in Young Women Than Young Men in the United States. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29791813 | PubMed |
| 13 | 37445915 | The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37445915 | PubMed |
| 14 | 38552205 | Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC. | ACS Chem Biol | 2024 | https://conductscience.org/library/papers/38552205 | PubMed |
| 15 | 29332333 | Epigallocatechin gallate from green tea exhibits potent anticancer effects in A-549 non-small lung cancer cells by inducing apoptosis, cell cycle arrest and inhibition of cell migration. | J BUON | 2017 | https://conductscience.org/library/papers/29332333 | PubMed |
| 16 | 23711146 | PI3K/AKT/mTOR signaling is involved in (-)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells. | Am J Chin Med | 2013 | https://conductscience.org/library/papers/23711146 | PubMed |
| 17 | 26794417 | EGCG induces lung cancer A549 cell apoptosis by regulating Ku70 acetylation. | Oncol Rep | 2016 | https://conductscience.org/library/papers/26794417 | PubMed |
| 18 | 38543009 | Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets. | Molecules | 2024 | https://conductscience.org/library/papers/38543009 | PubMed |
| 19 | 31777584 | Synergistic inhibition of lung cancer cells by EGCG and NF-κB inhibitor BAY11-7082. | J Cancer | 2019 | https://conductscience.org/library/papers/31777584 | PubMed |
| 20 | 36500365 | Induction of Apoptosis via Inactivating PI3K/AKT Pathway in Colorectal Cancer Cells Using Aged Chinese Hakka Stir-Fried Green Tea Extract. | Molecules | 2022 | https://conductscience.org/library/papers/36500365 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42793131 | Epigallocatechin Gallate Modulates the Cellular Response to Doxorubicin in HeLa Cervical Cancer Cells. | Biomolecules | 2026 | https://conductscience.org/library/papers/42793131 | PubMed |
| 41674940 | EGCG promotes apoptosis in BT-549 triple-negative breast cancer cells by targeting STAT3. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/41674940 | PubMed |
| 40871008 | Lipid-Based Nanotechnologies for Delivery of Green Tea Catechins: Advances, Challenges, and Therapeutic Potential. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40871008 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40161336
GET https://conductscience.org/api/papers/v1/40161336/references?page=2